Research programme: antivirals - Microbiotix

Drug Profile

Research programme: antivirals - Microbiotix

Alternative Names: MBX 468; MBX 685; MBX 769S

Latest Information Update: 26 Sep 2012

Price : $50

At a glance

  • Originator Microbiotix
  • Developer Microbiotix; University of Michigan
  • Class Cyclopropanes; Purine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cytomegalovirus infections; Hepatitis C; Herpesvirus infections; Influenza A virus H5N1 subtype
  • Discontinued Epstein-Barr virus infections; Hepatitis B

Most Recent Events

  • 26 Sep 2012 Preclinical development is ongoing in USA
  • 01 May 2012 Microbiotix receives Phase II SBIR grant from National Institute of Allergy and Infectious Diseases for methylenecyclopropane analogues development in Herpesvirus infections
  • 16 Sep 2011 Microbiotix initiates clinical development of its lead methylenecyclopropane candidate, cyclopropavir
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top